tbuckley/cabot-search huggingface dataset:
TELEHEALTH FOR IDENTIFICATION, TREATMENT, AND PATIENT SELF-MANAGEMENT OF HYPERTENSION: A MOUNT SINAI HEALTH SYSTEM NOVEL SCREENING APPROACH FOR NYC FIREFIGHTERS
Authors: Jeffrey A. Bander, Kathleen Grene, Kristin Allocco, Viola Spahiu, Rony Shimony, David Ores
Journal: Journal of the American College of Cardiology (2020)
Neurophysiological signatures in Alzheimer’s disease are distinctly associated with TAU, amyloid-β accumulation, and cognitive decline
Authors: Kamalini G. Ranasinghe, Jungho Cha, Leonardo Iaccarino, Leighton B. Hinkley, Alexander J. Beagle, Julie Pham, William J. Jagust, Bruce L. Miller, Katherine P. Rankin, Gil D. Rabinovici, Keith A. Vossel, Srikantan S. Nagarajan
Journal: Science Translational Medicine (2020)

Alpha and delta-theta brain oscillation deficits depict diverse associations with amyloid and TAU accumulations and with cognitive decline in AD.
PTH-018 Is dysphagia under investigated at endoscopy?
Authors: Georgina Chadwick, Jonathan Hoare
Journal: Endoscopy (2018)

<h3>Introduction</h3> The 2015 NICE guidelines recommend endoscopy (OGD) to investigate dysphagia, to rule out oesophageal cancer. However when performing these endoscopies it is important to look for other causes of dysphagia like gastro oesophageal reflux disease (GORD) and rarer conditions such as eosinophilic oesophagitis (EOE). The recently published BSG quality standards for endoscopy suggest that biopsies should be taken from two different sites in the oesophagus to rule out eosinophilic oesophagitis in those presenting with dysphagia/food bolus obstruction, where an alternative cause is not found. This study aimed to investigate the proportion of patients who had biopsies at endoscopy performed for dysphagia, and look at other investigations performed and final diagnosis made. <h3>Methods</h3> Using Scorpio all OGDs performed for dysphagia between Jan 2017 and March 2017 were identified. Primary outcome assessed was proportion of patient with dysphagia who had oesophageal biopsies performed, if no visible cause was found. Other outcomes assessed included biopsy findings, additional investigations performed and final diagnosis made. <h3>Results</h3> 155 OGDs were performed for dysphagia, 76.7% were urgent referrals, mean (±SD) age of patient was 62.3 (±17.3) years. 108 (69.67%) patients had no visible cause for dysphagia identified at endoscopy, but only 55 (50.9%) of these patients had an oesophageal biopsy. Histology findings for these 48 cases are reported in table 1. 21 (19.4%) patients with no visible lesion had further investigation after endoscopy: 8 (7.4%) barium swallow, 9 (8.3%) CT and 3 (2.8%) manometry. Final diagnosis for all patients who had no structural lesion (6 months after initial OGD): 64 (59.3%) had no diagnosis, 26 (24.1%) had GORD, 5 (4.6%) had a dysmotility disorder, 4 (3.7%) had EoE and 6 (5.6%) had BE. <h3>Conclusion</h3> Two thirds of patients had no visible cause of dysphagia identified at endoscopy, but only half of these patients had oesophageal biopsies taken as recommended by the BSG. Where there were taken the most common finding was normal histology (41.8%), while 40.0% had GORD and only 7.3% had EOE. Nearly 60% of patients with dysphagia who are referred for endoscopy have no formal diagnosis made 6 months after initial endoscopy.
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Authors: Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew S Paulson, Mitesh J Borad, David Gallinson, Adrian G Murphy, Do-Youn Oh, Efrat Dotan, Daniel V Catenacci, Eric Van Cutsem, Tao Ji, Christine F Lihou, Huiling Zhen, Luis Féliz, Arndt Vogel
Journal: The Lancet Oncology (2020)
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis
Authors: Zhiyi Lan, Nafees Ahmad, Parvaneh Baghaei, Linda Barkane, Andrea Benedetti, Sarah K Brode, James C M Brust, Jonathon R Campbell, Vicky Wai Lai Chang, Dennis Falzon, Lorenzo Guglielmetti, Petros Isaakidis, Russell R Kempker, Maia Kipiani, Liga Kuksa, Christoph Lange, Rafael Laniado-Laborín, Payam Nahid, Denise Rodrigues, Rupak Singla, Zarir F Udwadia, Dick Menzies, N Ahmad, P Baghaei, L Barkane, A Benedetti, SK Brode, JCM Brust, JR Campbell, VWL Chang, D Falzon, L Guglielmetti, P Isaakidis, RR Kempker, M Kipiani, L Kuksa, Z Lan, C Lange, R Laniado-Laborín, P Nahid, D Rodrigues, R Singla, ZF Udwadia, D Menzies
Journal: The Lancet Respiratory Medicine (2020)
PERFORMANCE OF A NEW RISK PREDICTION SCORE FOR STROKE ONE YEAR AFTER TAVR COMPARED WITH CHADS2AND CHA2DS2VASC SCORES
Authors: Paul Muutu Ndunda, Peter Tadros, Mark Wiley, Gregory Muehlebach, George Zorn, Heyrettin Okut, Elizabeth Ablah, Kallail K. James, Zaher Fanari
Journal: Journal of the American College of Cardiology (2020)
WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY PREDICTS THROMBOEMBOLIC RISK IN ATRIAL FIBRILLATION
Authors: Syed Bukhari, Amr Barakat, Sandeep Jain, Amy Brownell, Sasa Zivkovic, Yvonne S. Eisele, William Follansbee, Samir F. Saba, Prem Soman
Journal: Journal of the American College of Cardiology (2020)
THE UTILITY OF FRAMINGHAM SCORE FOR RISK STRATIFICATION AMONG PATIENTS UNDERGOING LIVER TRANSPLANT EVALUATION
Authors: Tanya Doctorian, Srishti Nayak, Shuktika Nandkeolyar, Colleen Fearon, David Tryon, Antoine Sakr, Liset Stoletniy, Michael Volk, Dmitry Abramov
Journal: Journal of the American College of Cardiology (2020)
DIAGNOSTIC AND PROGNOSTIC UTILITY OF RIGHT VENTRICULAR STRAIN IN ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY: A PROSPECTIVE MULTICENTER REGISTRY
Authors: Mayooran Namasivayam, Samuel Bernard, Philippe Bertrand, Frank I. Marcus, Luisa Mestroni, Jeffrey Saffitz, Jeffrey A. Towbin, Wojciech Zareba, Michael Picard
Journal: Journal of the American College of Cardiology (2020)
OBESITY-PARADOX AND SHORT-TERM NEUROLOGIC RECOVERY IN SURVIVORS OF OUT OF HOSPITAL CARDIAC ARREST
Authors: Tariq Odeh, Jason Grady, Katie Atwell, Ankit Patel, Allison Dupont, Tomohiro Oshimura, Pradyumna Tummala, Nima Ghasemzadeh
Journal: Journal of the American College of Cardiology (2020)
SADDLE PULMONARY EMBOLISM SUCCESSFULLY MANAGED BY THROMBUS ASPIRATION FOLLOWED BY ULTRASOUND-ENHANCED CATHETER DIRECTED THROMBOLYSIS
Authors: Khader H. Herzallah, Yehia Saleh, Sherif Elkinany, Ola Abdelkarim, Mahmoud Abdelnabi, Abdallah Almaghraby
Journal: Journal of the American College of Cardiology (2020)
TEMPORAL TRENDS IN TRANSRADIAL ACCESS DURING PCI IN RELATION TO BLEEDING RISK: INSIGHTS FROM A LARGE SINGLE-CENTER REGISTRY
Authors: Michael Healy, Usman Baber, Nitin Barman, Joseph Sweeny, Prathyusha Reddy, Pooja Vijay, George D. Dangas, Roxana Mehran, Annapoorna Subhash Kini, Samin K. Sharma
Journal: Journal of the American College of Cardiology (2020)
Covid-19: Medical conferences around the world are cancelled after US cases are linked to Massachusetts meeting
Authors: Abi Rimmer
Journal: BMJ (2020)

Medical conferences around the world have been cancelled because of fears about covid-19 after a meeting in Massachusetts was linked to 70 suspected cases.

The Massachusetts Department of Public Health announced earlier this month that 15 suspected cases of covid-19 in the state had a direct connection to a meeting of staff from the biotech company Biogen, held in Boston in late February.1

Two days later the Massachusetts state governor, Charlie Baker, declared a state of emergency.2 Massachusetts currently has six confirmed cases of covid-19 and 89 suspected cases.3

Fears about covid-19 have also led to numerous medical conferences around the world being postponed or cancelled. In the UK …
YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma
Authors: Yan Xu, Mariateresa Fulciniti, Mehmet K. Samur, Matthew Ho, Shuhui Deng, Lanting Liu, Kenneth Wen, Tengteng Yu, Zuzana Chyra, Sanika Dereibal, Li Zhang, Yao Yao, Chandraditya Chakraborty, Eugenio Morelli, Na Li, Michael A. Lopez, Tommaso Perini, Shidai Mu, Gang An, Rafael Alonso, Giada Bianchi, Yu-Tzu Tai, Kenneth C. Anderson, Lugui Qiu, Nikhil C. Munshi
Journal: Blood (2020)
Head and neck sarcomas: A comprehensive cancer center experience.
Authors: Mohamedtaki Abdulaziz Tejani, John A. Ridge, Thomas J Galloway, Margaret von Mehren
Journal: Journal of Clinical Oncology (2012)

10064 Background: Head/neck sarcomas are rare, accounting for 1% of head/neck malignancies and 5% of sarcomas. There are about 1000 cases/year in the U.S. comprising of many histologic subtypes making rigorous study of these tumors difficult. Outcomes have historically been worse in this anatomic group due to unique obstacles encountered during their treatment. Methods: We retrospectively analyzed cases of head/neck soft tissue sarcomas treated at Fox Chase Cancer Center (1999–2009). Study objectives were to describe clinicopathologic characteristics, treatment and outcomes of adult head/neck sarcoma patients and identify prognostic factors for disease control and survival. Cox proportional hazards regression analysis was performed to identify predictors of DFS and OS. The HR and 95% CI for Cox model and median DFS/OS from Kaplan-Meier curves were calculated. Results: 31 patients were identified. Median age was 50 (range 15–91). 23 patients were male. Most tumors were high grade (25) and almost all were localized at presentation (29). Common histologies were synovial cell (6), rhabdomyosarcoma (5), angiosarcoma (4), lipsarcoma (4) and leiomyosarcoma (3). 25 patients with localized stage underwent excision: 9 had surgical resection only, 10 had surgical resection with neo/adjuvant radiation and 6 had surgical resection as well as neo/adjuvant chemotherapy and radiation. 7 patients required re-excision to achieve negative margins. Median DFS was 1.1 years (95% CI: 0.7–12.1) and median OS was 3.3 years (95% CI: 2.1-5.4). Of 16 patients with recurrent disease, 12 were local. Patients with positive margins had worse DFS (p=0.04) and OS (p=0.03). Tumors greater than 5cm were associated with worse DFS (p=0.07). Age and grade did not correlate with outcome. Conclusions: Head/neck sarcomas are difficult to completely excise due to anatomic constraints and local recurrence rates are high. Achieving a negative margin is critical in improving outcome. Median DFS and OS are worse than those achieved with other subsites. Head/neck sarcomas are best managed in a multi-disciplinary setting. [Table: see text]
CLO20-069: Evaluation and analysis of postoperative complications after primary cytoreduction for 47 cases of advanced epithelial ovarian cancer at stage IIIc and IV RUNNING HEAD (maximum 40 characters): Complications after primary cytoreduction in ovarian cancer
Authors: Ying Zhou, Chenchen Zhu, Zhen Shen, Yanhu Xie, Wei Zhang, Jing Zhu, Tianjiao Zhang, Min Li, Jiwei Qin, Shuai Yin, Rongzhu Chen, Wei Wei, Sinan Sun, Guihong Wang, Zheng Zhou, Hanhui Yao, Dabao Wu, Björn Nashan
Journal: Journal of the National Comprehensive Cancer Network (2020)

"CLO20-069: Evaluation and analysis of postoperative complications after primary cytoreduction for 47 cases of advanced epithelial ovarian cancer at stage IIIc and IV RUNNING HEAD (maximum 40 characters): Complications after primary cytoreduction in ovarian cancer" published on 20 Mar 2020 by National Comprehensive Cancer Network.
Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non–Small Cell Lung Cancer After Second-Line Treatment Failure
Authors: Xiangyu Zhang, Yi Xiong, Qing Xia, Fang Wu, Lingli Liu, Yuling Zhou, Liang Zeng, Chunhua Zhou, Chen Xia, Wenjuan Jiang, Dehua Liao, Lili Xiao, Li Liu, Haiyan Yang, Rui Guan, Kunyan Li, Jing Wang, Guang Lei, Yongchang Zhang, Nong Yang
Journal: JAMA Network Open (2020)

<h3>Importance</h3> There is currently no standard treatment strategy for patients with advanced non–small cell lung cancer (NSCLC) without driver gene variation after failure of 2 or more lines of chemotherapy. <h3>Objective</h3> To assess the efficacy and safety of apatinib combined with oral vinorelbine. <h3>Design, Setting, and Participants</h3> This phase 2 prospective nonrandomized clinical trial evaluating the efficacy and safety of apatinib plus vinorelbine recruited patients from Hunan Cancer Center, Hunan, China, from January 1, 2017, to November 30, 2018. Eligible patients were those with wild-type advanced NSCLC whose disease did not respond to at least 2 lines of chemotherapy. Patients were evaluated until December 31, 2019. Data were analyzed from July 2019 to December 2019. <h3>Intervention</h3> Apatinib at an initial dose of 500 mg once daily and oral vinorelbine 60 mg/m<sup>2</sup>once weekly were administered until disease progression, patient withdrawal, or occurrence of unacceptable toxic effects. <h3>Main Outcomes and Measures</h3> The primary end point was overall response rate. Secondary end points were overall survival, progression-free survival, and safety. <h3>Results</h3> The potential efficacy of apatinib plus vinorelbine was identified using drug susceptibility assay based on 3-dimensional coculture of tumor cells derived from 3 patients with lung adenocarcinoma. Among 30 patients enrolled, the median (range) age was 63 (34-78) years and 18 (60%) were men. Most patients (27 patients [90%]) had stage IV disease, and the median (range) number of prior unsuccessful treatments was 2 (2-5) lines of chemotherapy. Twenty-five patients (83%) completed the treatment, while 5 patients (17%) discontinued treatment owing to intolerable adverse events. The overall response rate was 36.7% (11 patients) and the disease control rate was 76.7% (23 patients). The median progression-free survival was 4.5 (95% CI, 2.4-6.6) months, and the median overall survival was 10.0 (95% CI, 4.8-17.1) months. Hand-foot syndrome was the most common adverse event observed, including grade 3 hand-foot syndrome observed in 5 patients (17%) and grade 4 hand-foot observed in 1 patient (3%). Grade 3 weakness was observed in 1 patient (3%). <h3>Conclusions and Relevance</h3> These findings suggest that apatinib combined with oral vinorelbine is a potentially effective regimen with an acceptable safety profile. This regimen may have potential as a treatment option for patients with wild-type advanced NSCLC whose disease failed at least 2 prior lines of chemotherapy. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT03652857
THIRTY-DAY CAUSES AND READMISSION RATES FOR PATIENTS UNDERGOING LEFT ATRIAL APPENDAGE OCCLUSION DEVICE PLACEMENT: INSIGHTS FROM THE NATIONAL READMISSION DATABASE 2016
Authors: Sagar Ranka, Farhad A. Sami, Prakash Acharya, Tarun Dalia, Arslan Naeem, Apte Nachiket, Madhu Reddy
Journal: Journal of the American College of Cardiology (2020)
PREVALENCE OF CLINICAL FEATURES IN RECURRENT PERICARDITIS PATIENTS
Authors: Vardhmaan Jain, Muhammad Furqan, Ray Tabucanon, Bryce Montanè, Mohamed Khayata, Agam Bansal, Medhat Farwati, Manpreet Kaur, Beni Rai Verma, Tom Kai Ming Wang, Nicholas Kassis, Christine Louise Jellis, Deborah Kwon, Chadi Ayoub, Allan Klein
Journal: Journal of the American College of Cardiology (2020)
THE INCIDENCE OF STROKE WITHIN 30 DAYS AFTER MITRAL CLIP A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Manpreet Kaur, Shameer Khubber, Beni Rai Verma, Chandramohan Meenakshisundaram, Leon Zhou, Mohamed M. Gad, Keerat Rai Ahuja, Kamalpreet Dhaliwal, Vardhmaan Jain, Najdat Bazarbashi, Anas Saad, Omar Abdelfattah, Shashank Shekhar, Toshiaki Isogai, Agam Bansal, Samir R. Kapadia
Journal: Journal of the American College of Cardiology (2020)
LONG-TERM OUTCOME COMPARISON BETWEEN MECHANICAL AND BIOPROSTHETIC VALVE IN END-STAGE RENAL DISEASE
Authors: Takuya Ogami, Eric Zimmermann, Roger Zhu, Yuming Ning, Paul A. Kurlansky, Koji Takeda, Isaac George, Dimitrios Avgerinos, Hiroo Takayama
Journal: Journal of the American College of Cardiology (2020)
LIPOPROTEIN SUBFRACTIONS ARE ASSOCIATED WITH ISCHEMIC STROKE AMONG 9,795 PATIENTS IN THE FIELD TRIAL
Authors: Anthony C. Keech, Peter P. Toth, Andrzej Januszewski, Rachel O’Connell, Liping Li, David Sullivan, Marja-Riitta Taskinen, Graeme Hankey, Neil E. Anderson, Matti Romo, Paul L. Drury, Gerald Watts, James D. Best, Jean-Claude Ansquer, Steven R. Jones, Alicia J. Jenkins
Journal: Journal of the American College of Cardiology (2020)
SAFETY AND EFFICACY OF MACITENTAN IN ELDERLY PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH): INSIGHTS FROM SERAPHIN
Authors: David Langleben, Richard Channick, Marion Delcroix, Nazzareno Galiè, Ardeschir Ghofrani, Pavel Jansa, Sanjay Mehta, Tomas Pulido, Rogerio Souza, Gérald Simonneau, B.K.S. Sastry, Adam Torbicki, Nicolas Martin, Loïc Perchenet, Olivier Sitbon
Journal: Journal of the American College of Cardiology (2020)
Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II.
Authors: Robert Glynne-Jones, Roger James, Helen Meadows, Rubina Begum, David Cunningham, John Northover, Jonathan A. Ledermann, Sandra Beare, Latha Kadalayil, David Sebag-Montefiore
Journal: Journal of Clinical Oncology (2012)

4004 Background: In the ACT I trial, relapse-free survival was improved with CRT compared to RT alone, but the CR rate at 6 weeks was similar (39% CRT, 30% RT alone; p=0.08). Most studies assessed CR between 6 and 12 weeks following completion of CRT. We investigated the association between observation of CR at 3 different time-points and progression-free and overall survival (PFS, OS), to determine the optimal time to assess this early endpoint. Methods: ACT II recruited 940 pts between 2001 and 2008. It compared, in a factorial design, CisP versus MMC when combined with 5-FU CRT, and two cycles of maintenance chemotherapy versus no maintenance. CR (complete absence of tumour and node negative) was assessed by rectal exam or imaging at 11, 18 and mandated CT at 26 weeks after the start of CRT. Median follow-up was 5 years. Pts were excluded from analysis if assessment was not done/ missing at one or more time points (n=245). Data from 695 pts were analysed. Results: Pt characteristics (all 940) median age 58 years; tumour site – canal (84%), margin (14%); stage T1-T2 (52%), T3-T4 (46%); N+ (32%), N0 (62%). CisP did not improve OS (HR: 0.96, p=0.89) or PFS (HR: 0.85, p=0.43) compared to MMC. This is consistent with the lack of an absolute difference at 18 and 26 weeks, but not at 11 weeks (where a difference was found). CR patients (compared to not-CR) had a significantly lower risk of progression/death. The association between these outcomes and response was strongest at 26 weeks. 202/695 (29%) pts not in CR at 11 weeks were CR at 26 weeks. Conclusions: 29% of pts not in CR at 11 weeks achieved CR at 26 weeks. Early surgical salvage would not have been appropriate for these pts. We recommend assessment at 26 weeks in future trials. [Table: see text]
SARS-CoV-2 Infection in Children
Authors: Xiaoxia Lu, Liqiong Zhang, Hui Du, Jingjing Zhang, Yuan Y. Li, Jingyu Qu, Wenxin Zhang, Youjie Wang, Shuangshuang Bao, Ying Li, Chuansha Wu, Hongxiu Liu, Di Liu, Jianbo Shao, Xuehua Peng, Yonghong Yang, Zhisheng Liu, Yun Xiang, Furong Zhang, Rona M. Silva, Kent E. Pinkerton, Kunling Shen, Han Xiao, Shunqing Xu, Gary W.K. Wong
Journal: New England Journal of Medicine (2020)

SARS-CoV-2 Infection in Children In this report, investigators in Wuhan, China, describe the spectrum of Covid-19 illness in children under the age of 16 years. Of 1391 children assessed and tested...
Truncating BRIP1 mutations are uncommon in 17q-linked hereditary prostate cancer families
Authors: Anna Ray, Kimberly Zuhlke, Gregory Johnson, Albert Levin, Julie Douglas, Kathleen Cooney
Journal: Cancer Research (2008)

3114  In a genome-wide scan (GWS) of 175 multiplex prostate cancer (PCa) families from the University of Michigan Prostate Cancer Genetics Project (PCGP), linkage was observed to markers on chromosome 17q21-24, a region which includes two breast cancer susceptibility genes, BRCA1 and BRIP1. BRIP1 is a Fanconi anemia gene (FANCJ) whose protein binds directly to the BRCT domain of BRCA1 and plays a role in DNA damage repair. Like BRCA1, germline, protein truncating mutations in BRIP1 have been identified in hereditary breast and ovarian cancer families and confer an increased risk of breast cancer to carriers. Here we examine the role of BRIP1 mutations in hereditary PCa. All BRIP1 exons and intron/exon boundaries were directly sequenced in 1 individual from each of 94 PCGP families displaying linkage (non-parametric linkage score > 0) to chromosome 17q. These families had an average of 4.1 confirmed PCa cases per family (range = 2-14), and the mean age of PCa diagnosis of confirmed cases within a pedigree was 63.7 years (range = 45.7-78.3). Thirty-seven of the 94 families contained at least 1 breast cancer (BrCa) case, and 8 families contained at least 1 ovarian cancer case. The individuals sequenced included 88 men with PCa and 6 women with BrCa. No protein truncating mutations were identified in any of the individuals sequenced. However, 24 single nucleotide polymorphisms (SNPs) including 7 missense mutations were observed; 3 of these missense mutations were previously unreported in dbSNP, and 2 of the 7 were predicted to be deleterious to the protein by both SIFT and PolyPhen. Overall, no individual was wild type at all 24 SNPs, and 59 individuals had at least one missense mutation. One individual was heterozygous for 3 different missense variants. The data presented here suggest that BRIP1 truncating mutations are not common PCa susceptibility mutations and do not account for the linkage to chromosome 17q observed in the PCGP GWS. Note that these same individuals from the 17q-linked families were previously screened for BRCA1 mutations. Only one BRCA1 truncating mutation was identified, but several missense BRCA1 variants were detected. Additional investigation is underway to determine the significance of the observed BRCA1 and BRIP1 missense mutations in hereditary PCa.
CRISPR/Cas9-Mediated miR-29b Editing as a Treatment of Different Types of Muscle Atrophy in Mice
Authors: Jin Li, Lijun Wang, Xuejiao Hua, Haifei Tang, Rui Chen, Tingting Yang, Saumya Das, Junjie Xiao
Journal: Molecular Therapy (2020)

Muscle atrophy is the loss of skeletal muscle mass and strength in response to diverse catabolic stimuli. At present, no effective treatments except exercise have been shown to reduce muscle atrophy clinically. Here, we report that CRISPR/Cas9-mediated genome editing through local injection into gastrocnemius muscles or tibialis anterior muscle efficiently targets the biogenesis processing sites in pre-miR-29b. In vivo, this CRISPR-based treatment prevented the muscle atrophy induced by angiotensin II (AngII), immobilization, and denervation via activation of the AKT-FOXO3A-mTOR signaling pathway and protected against AngII-induced myocyte apoptosis in mice, leading to significantly increased exercise capacity. Our work establishes CRISPR/Cas9-based gene targeting on miRNA as a potential durable therapy for the treatment of muscle atrophy and expands the strategies available interrogating miRNA function in vivo.
EFFECT OF INSTITUTIONAL TRANS-CATHETER AORTIC VALVE REPLACEMENT (TAVR) VOLUME ON MORTALITY: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Devika Kir, Kayle Shapero, Saurav Chatterjee, Alyssa Grimshaw, August Oddleifson, Erica Spatz, Andrew Goldsweig, Nihar R. Desai
Journal: Journal of the American College of Cardiology (2020)